Study PRO-101: Experience implementing an ALS community advisory board in early phase drug development
ProJenX has deep roots in the ALS community. Named for Jenifer Estess, who founded the nonprofit Project ALS with her family and friends after receiving an ALS diagnosis at 35, the development of our ALS clinical candidate prosetin has been guided by the ALS community since day 1. ProJenX formed a Community Advisory Board at inception, which has allowed us to fully integrate ALS lived expertise into decision-making ranging from regulatory hurdles to early phase clinical trial design. At the 2024 Northeast ALS Consortium annual meeting, we are pleased to co-present on this experience with members of our CAB.
CAB members Gretchen Roy and Michele Stellato share their backgrounds and experience with the ProJenX CAB below.
Gretchen Roy, ALS caregiver:
Michele Stellato, living with ALS:
Click below for a downloadable version of the presentation:
